Prevention of type 2 diabetes and its macrovascular complications: Whom, when, and how should we treat?

Current Opinion in Endocrinology and Diabetes

Volumn 10, Issue 4, 2003, Pages 229-236

  Panzer, Claudia ^a   Brieke, Andreas ^b   Ruderman, Neil ^a,c  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TUFTS MEDICAL CENTER   (United States)

^c BOSTON MEDICAL CENTER   (United States)

Author keywords

AMP activated protein kinase; Cardiovascular disease; Impaired glucose tolerance; Insulin resistance syndrome; Metabolic syndrome

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADENYLATE KINASE; ADIPONECTIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; MALONYL COENZYME A; METFORMIN; PIOGLITAZONE; PRAVASTATIN; RAMIPRIL; SIMVASTATIN; STATIN; TROGLITAZONE;

CARDIOVASCULAR RISK; DIET THERAPY; DISEASE ACTIVITY; DISEASE COURSE; DISEASE PREDISPOSITION; ENZYME ACTIVITY; EXERCISE; GENE OVEREXPRESSION; GLUCOSE TOLERANCE; HUMAN; INCIDENCE; INSULIN RESISTANCE; INSULIN SENSITIVITY; ISCHEMIC HEART DISEASE; LIFESTYLE; LIPID STORAGE; METABOLIC DISORDER; MICROALBUMINURIA; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PREVALENCE; REVIEW; SIGNAL TRANSDUCTION; SURVIVAL RATE; TREATMENT PLANNING; VASCULAR DISEASE;

EID: 0242559050     PISSN: 10683097     EISSN: None     Source Type: Journal    
DOI: 10.1097/00060793-200308000-00001     Document Type: Review

References (60)

1. Stamler J, Vaccaro O, Neaton JD, Wentworth D: Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993, 16:434-444.
2. Kannel WB, McGee DL: Diabetes and cardiovascular disease. The Framingham study. JAMA 1979, 241:2035-2038.
3. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002, 106:3143-3421.
4. Vijan S, Hayward RA: Treatment of hypertension in type 2 diabetes mellitus: Blood pressure goals, choice of agents, and setting priorities in diabetes care. Ann Intern Med 2003, 138:593-602.
5. Gu K, Cowie CC, Harris MI: Diabetes and decline in heart disease mortality in US adults. JAMA 1999, 281:1291-1297.
6. Haffner SM, Lehto S, Ronnemaa T, et al: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998, 339:229-234.
7. American Diabetes Association: Standards of medical care for patients with diabetes mellitus. Diabetes Care 2003, 26(Suppl 1):S33-50.
8. Gaede P, Vedel P, Larsen N, et al.: Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003, 348:383-393. This study compared a multifactorial strategy that included stepwise implementation of behavioral modification and pharmacologic therapy targeted at hyperglycemia, hypertension, dyslipidemia, and microalbuminuria, along with secondary prevention of cardiovascular disease with conventional aspirin treatment in patients with type 2 diabetes and microalbuminuria. The multifactorial intensified intervention reduced the incidence of cardiovascular and microvascular events by about 50%.
9. Prospective Diabetes Study UK (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS33). Lancet 1998, 352:837-853.
10. Prospective Diabetes Study UK (UKPDS) Group: Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998, 352:854-865.
11. UK Prospective Diabetes Study Group: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998, 317:703-713.
12. Tuomilehto J, Lindstrom J, Eriksson JG, et al.: Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001, 344:1343-1350. The Finnish Diabetes Prevention Study demonstrated in a long-term, randomized trial that type 2 diabetes can be prevented, or at least delayed, by changes in the lifestyles of high risk individuals targeted at reducing weight, total intake of fat and saturated fat, and increasing intake of fiber and physical activity.
13. Knowler WC, Barrett-Connor E, Fowler SE, et al.: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002, 346:393-403. The DPP demonstrated that type 2 diabetes can be prevented, or at least delayed, in high-risk individuals. Both lifestyle modification and metformin reduced the progression rates from IGT to diabetes, with lifestyle changes being more effective than metformin.
14. The Diabetes Prevention Program Research Group: Prevention of type 2 diabetes with troglitazone in the diabetes prevention program. Diabetes 2003, 52(supplement):A58.
15. Chiasson JL, Josse RG, Gomis R, et al.: Acarbose for prevention of type 2 diabetes mellitus: The STOP-NIDDM randomised trial. Lancet 2002, 359:2072-2077.
16. Diabetes Prevention Program Research Group: Effects of withdrawal from metformin on the development of diabetes in the Diabetes Prevention Program. Diabetes Care 2003, 26:977-980.
17. Eriksson KF, Lindgarde F: Prevention of type 2 (non-insulin-dependent) diabetes mellitus by diet and physical exercise: The 6-year Malmo feasibility study. Diabetologia 1991, 34:891-898.
18. Pan XR, Li GW, Hu YH, et al.: Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 1997, 20:537-544.
19. Buchanan TA, Xiang AH, Peters RK, et al.: Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes 2002, 51:2796-2803. This study demonstrated that treatment with troglitazone delayed or prevented the onset of type 2 diabetes in high-risk Hispanic women. The protective effect was associated with the preservation of pancreatic beta-cell function and appeared to be mediated by a reduction in the secretory demands placed on beta-cells by chronic insulin resistance.
20. Buchanan TA: Prevention of type 2 diabetes: What is it really? Diabetes Care 2003, 26:1306-1308.
21. Coutinho M, Gerstein HC, Wang Y, Yusuf S: The relationship between glucose and incident cardiovascular events: A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 1999, 22:233-240.
22. Hoogwerf BJ, Sprecher DL, Pearce GL, et al.: Blood glucose concentrations < or = 125 mg/dl and coronary heart disease risk. Am J Cardiol 2002, 89:596-599.
23. The Diabetes Prevention Program Research Group: Impact of lifestyle and metformin therapy on cardiovascular (CVD) risk factors and events in the Diabetes Prevention Program. Diabetes 2003, 52:A 169. Preliminary report of the DPP Research Group indicating that lifestyle interventions are significantly more effective than metformin in lowering traditional markers of cardiovascular risk over a follow-up period of 3 years.
24. The Diabetes Prevention Program Research Group: The effects of intensive lifestyle intervention (ILS) and metformin (MET) on C-reactive protein (CRP), tissue plasminogen activator (TPA) and fibrinogen (FIB) in the Diabetes Prevention Program (DPP). Diabetes 2003, 52:A18. Preliminary report of the DPP Research Group demonstrating that lifestyle intervention is more effective than metformin in reducing nontraditional markers of cardiovascular disease.
25. Eriksson KF, Lindgarde F: No excess 12-year mortality in men with impaired glucose tolerance who participated in the Malmo Preventive Trial with diet and exercise. Diabetologia 1998, 41:1010-1016.
26. Reaven GM: Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988, 37:1595-1607.
27. Reaven G: Syndrome X. Curr Treat Options Cardiovasc Med 2001, 3:323-332.
28. Neubauer E: Úeber Hyperglykaemie bei Hochdrucknephritis und die Beziehungen zwischen Glykaemie und Glukosurie beim Diabetes mellitus. Biochem Z 1910 25:284.
29. Dieterle P, Fehm H, Stroder W, et al.: Asymptomatic diabetes mellitus in hypertensive patients of normal weight: Glucose tolerance and serum levels of insulin and nonesterified fatty acids in essential hypertension. Ger Med Mon 1968, 13:478-483.
30. Bjorntorp P: Abdominal obesity and the development of noninsulin-dependent diabetes mellitus. Diabetes Metab Rev 1988, 4:615-622.
31. Haffner SM, Stern MP, Mitchell BD, et al.: Incidence of type II diabetes in Mexican Americans predicted by fasting insulin and glucose levels, obesity, and body-fat distribution. Diabetes 1990, 39:283-288.
32. Warram JH, Martin BC, Krolewski AS, et al.: Slow glucose removal rate and hyperinsulinemia precede the development of type II diabetes in the offspring of diabetic parents. Ann Intern Med 1990, 113:909-915.
33. Ruderman N, Chisholm D, Pi-Sunyer X, Schneider S: The metabolically obese, normal-weight individual revisited. Diabetes 1998, 47:699-713.
34. Vaag A, Henriksen JE, Beck-Nielsen H: Decreased insulin activation of glycogen synthase in skeletal muscles in young nonobese Caucasian first-degree relatives of patients with non-insulin-dependent diabetes mellitus. J Clin Invest 1992, 89:782-788.
35. Perseghin G, Ghosh S, Gerow K, Shulman GI: Metabolic defects in lean nondiabetic offspring of NIDDM parents: A cross-sectional study. Diabetes 1997, 46:1001-1009.
36. Haffner SM, Mykkanen L, Festa A, et al.: Insulin-resistant prediabetic subjects have more atherogenic risk factors than insulin-sensitive prediabetic subjects: Implications for preventing coronary heart disease during the prediabetic state. Circulation 2000, 101:975-980.
37. Morales PA, Mitchell BD, Valdez RA, et al.: Incidence of NIDDM and impaired glucose tolerance in hypertensive subjects. The San Antonio Heart Study. Diabetes 1993, 42:154-161.
38. Ferrari P, Weidmann P, Shaw S, et al.: Altered insulin sensitivity, hyperinsulinemia, and dyslipidemia in individuals with a hypertensive parent. Am J Med 1991, 91:589-596.
39. Mayer-Davis EJ, D'Agostino R Jr, Karter AJ, et al.: Intensity and amount of physical activity in relation to insulin sensitivity: the Insulin Resistance Atherosclerosis Study. JAMA 1998, 279:669-674.
40. Alexander CM, Landsman PB, Teutsch SM, Haffner SM: NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 2003, 52:1210-1214.
41. Wilson PF, D'Agostino RB, Parise H, Meigs JB: The metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Diabetes 2002, 51:A242.
42. Lakka HM, Laaksonen DE, Lakka TA, et al.: The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002, 288:2709-2716.
43. Despres JP, Lamarche B, Mauriege P, et al.: Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 1996, 334:952-957.
44. Yip J, Facchini FS, Reaven GM: Resistance to insulin-mediated glucose disposal as a predictor of cardiovascular disease. J Clin Endocrinol Metab 1998, 83:2773-2776.
45. Meigs JB, Mittleman MA, Nathan DM, et al.: Hyperinsulinemia, hyperglycemia, and impaired hemostasis: The Framingham Offspring Study. JAMA 2000, 283:221-228.
46. Festa A, D'Agostino R Jr, Howard G, et al.: Chronic subclinical inflammation as part of the insulin resistance syndrome: The Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000, 102:42-47.
47. Chen NG, Holmes M, Reaven GM: Relationship between insulin resistance, soluble adhesion molecules, and mononuclear cell binding in healthy volunteers. J Clin Endocrinol Metab 1999, 84:3485-3489.
48. Abbasi F, Asagmi T, Cooke JP, et al.: Plasma concentrations of asymmetric dimethylarginine are increased in patients with type 2 diabetes mellitus. Am J Cardiol 2001, 88:1201-1203.
49. The Diabetes Prevention Program Research Group: The effect of intensive lifestyle intervention (ILS) and metformin (MET) on the incidence of the metabolic syndrome among participants in the diabetes prevention program (DPP). Diabetes 2003, 52(supplement):A58. Preliminary report of the DPP research group showing a high incidence of the metabolic syndrome in the DPP population and the effectiveness of lifestyle intervention and to a lesser degree of metformin in diminishing its prevalence.
50. Xiang AH, Peters R, Kjos S, et al.: Continued protection from diabetes during treatment of the TRIPOD cohort with pioglitazone. Diabetes 2003, 52:A75.
51. Heart Outcomes Prevention Evaluation Study Investigators: Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy. Lancet 2000, 355:253-259.
52. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: A randomised placebo-controlled trial. Lancet 2003, 361:2005-2016.
53. Pyorala K, Ballantyne C, Lee M, et al.: Reduction of coronary events by simvastatin in non-diabetic coronary heart disease patients with and without the metabolic syndrome: Subgroup analyses of the Scandinavian Simvastatin Survival Study (4S). Diabetes 2003, 52(supplement):A19.
54. McGarry JD: Banting lecture 2001: Dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. Diabetes 2002, 51:7-18.
55. Ruderman NB, Saha AK, Vavvas D, Witters LA: Malonyl-CoA, fuel sensing, and insulin resistance. Am J Physiol 1999, 276:E1-E18.
56. Hardie DG, Carling D: The AMP-activated protein kinase: Fuel gauge of the mammalian cell? Eur J Biochem 1997, 246:259-273.
57. Ruderman NB, Cacicedo JM, Itani S, et al.: Malonyl-CoA and AMP-activated protein kinase (AMPK): Possible links between insulin resistance in muscle and early endothelial cell damage in diabetes. Biochem Soc Trans 2003, 31:202-206. Article reviewing evidence that insulin resistance in muscle and the endothelial cell dysfunction thought to antedate and contribute to the pathogenesis of atherosclerosis in diabetes occur by a similar mechanism.
58. Yamauchi T, Kamon J, Waki H, et al.: Globular adiponectin protected ob/ ob mice from diabetes and ApoE-deficient mice from atherosclerosis. J Biol Chem 2003, 278:2461-2468.
59. Tomas E, Tsao TS, Saha AK, et al.: Enhanced muscle fat oxidation and glucose transport by ACRP30 globular domain: Acetyl-CoA carboxylase inhibition and AMP-activated protein kinase activation. Proc Natl Acad Sci U S A 2002, 99:16309-16313.
60. Okamoto Y, Kihara S, Ouchi N, et al.: Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation 2002, 106:2767-2770.